The Gastrointestinal Adverse Event Profile of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

被引：0

|

作者：

Stewart, Murray W.

Reusch, Jane E. B.

Bush, Mark A.

Yang, Fred

Rosenstock, Julio

机构：

来源：

DIABETES | 2009年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A161 / A161

页数：1

相关论文

共 50 条

[1] Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes
Setji, Tracy
Feinglos, Mark
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (03) : 229 - 238
[2] Albiglutide, a long-acting GLP-1-receptor agonist, for the treatment of type 2 diabetes: an analysis of gastrointestinal adverse events over time
Stewart, M. W.
Reusch, J. E. B.
Bush, M. A.
Yang, F.
Rosenstock, J.
DIABETOLOGIA, 2009, 52 : S302 - S303
[3] Albiglutide, a Long-Acting GLP-1 Receptor Agonist, Improves Glycemia in Type 2 Diabetes: Time-Course Analysis
Reusch, Jane E. B.
Rosenstock, Julio
Bush, Mark A.
Yang, Fred
Stewart, Murray W.
DIABETES, 2009, 58 : A123 - A123
[4] Population Pharmacokinetics of Albiglutide (Syncria®), a Long-Acting GLP-1 Receptor Agonist, Supports Weekly or Less Frequent Dosing in Type 2 Diabetes
Bush, Mark A.
Stewart, Murray W.
Rosenstock, Julio
Yang, Fred
DIABETES, 2010, 59 : A163 - A163
[5] The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly and Monthly Dosing
Rosenstock, Julio
Reusch, Jane E. B.
Bush, Mark A.
Yang, Fred
Stewart, Murray W.
DIABETES, 2009, 58 : A43 - A43
[6] Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Rosenstock, Julio
Yang, Fred
Reusch, Jane
Stewart, Murray
Bush, Mark
DIABETES CARE, 2009, 32 (10) : 1880 - 1886
[7] Albiglutide, a long-acting GLP-1 mimetic: pharmacodynamics, pharmacokinetics, safety and tolerability in subjects with type 2 diabetes
Stewart, M. W.
Matthews, J.
De Boever, E. H.
Dobbins, R. L.
Hodge, R. J.
Walker, S. E.
Holland, C. H.
Bush, M. A.
DIABETOLOGIA, 2008, 51 : S347 - S347
[8] Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide (Syncria®), a long-acting GLP-1 mimetic, in subjects with type 2 diabetes
Stewart, Murray W.
Matthews, Jessica
De Boever, Erika H.
Dobbins, Robert L.
Hodge, Rebecca J.
Walker, Susan E.
Holland, Claire H.
Bush, Mark A.
DIABETES, 2008, 57 : A154 - A154
[9] Semaglutide - a novel long-acting GLP-1 receptor agonist with proven reduction in cardiovascular events in type 2 diabetes
Seufert, Jochen
Nauck, Michael A.
Gallwitz, Baptist
DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (02) : 141 - 148
[10] Drug-Drug Interactions of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, with Warfarin and Digoxin in Healthy Subjects
Bush, Mark
Scott, Rhona
Zhi, Hui
Watanalumlerd, Prapoch
Lewis, Eric
DIABETES, 2011, 60 : A601 - A601

← 1 2 3 4 5 →